Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cod.14496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Old but not forgotten: Vesicular hand dermatitis from a copper-containing intrauterine device.
Contact Dermatitis
April 2024
Department of Dermatology, University Hospital Antwerp (UZA), Research Group Immunology, University of Antwerp, Antwerp, Belgium.
Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
J Infect Dis
October 2022
Columbia University College of Physicians and Surgeons, New York, New York, USA.
After 25 years of varicella vaccination in the United States, classic varicella and its complications have become an uncommon occurrence. The clinical manifestation of varicella among vaccinated persons is usually modified, with fewer skin lesions, mostly maculopapular, and milder presentation. However, the potential for severe manifestations from varicella still exists among both vaccinated and unvaccinated persons, and thus healthcare providers should keep varicella in the differential diagnosis of a maculopapular or vesicular rash.
View Article and Find Full Text PDFMonkeypox: the resurgence of forgotten things.
Epidemiol Health
April 2023
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Monkeypox, a rare zoonotic disease, is primarily prevalent in Central and Western Africa. However, monkeypox is emerging as a worldwide concern due to the 2022 monkeypox outbreak, which is the first instance of widespread community transmission outside Africa. Monkeypox is caused by the monkeypox virus, which belongs to the genus Orthopoxvirus and presents as a vesicular-pustular disease that may be preceded by fever, malaise, and other constitutional symptoms.
View Article and Find Full Text PDFForgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
CNS Spectr
December 2016
1Department of Psyshiatry, University of California,San Diego,California,USA.
The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, amantadine, ginkgo biloba extract, and the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine have compelling data.
View Article and Find Full Text PDFModern drug delivery strategies applied to natural active compounds.
Expert Opin Drug Deliv
June 2017
a Department of Drug Sciences , University of Catania, Catania , Italy.
Colloidal drug delivery systems (CDDSs) are innovative carriers that have been studied in pharmaceutical field from many years to overcome unfavorable physical and chemical features of synthetic drugs. Recently the use of CDDS as carriers for phytochemicals has seen an exponential increase which, in some cases, has led to the rediscovery of ancient and forgotten natural molecules. Area covered: This article focuses on the main features of CDDS, particularly micro- and nanoemulsions, vesicular carriers and micro- and nanoparticles, loaded with natural active compounds.
View Article and Find Full Text PDF